Prevention of chemotherapy-induced leukemia and of leukemia relapses
- 15 Downloads
Fifty percent of patients with the myelodysplastic syndrome, frequently following treatment by radiation or chemotherapy, have prognostically unfavorable deletions of the long arms of chromosomes 5 and 7, or trisomy 8, as have the 25% of patients with acute myeloblastic leukemia where remissions last 6–12 months, and where relapse cannot be prevented. In contrast, patients with prognostically favorable cytogenetics (translocation 15; 17 or 8; 21 or inversion 16) maintenance chemotherapy may prevent relapses. Of chronic myelocytic leukemia patients, 85% can achieve hematological remission with interferon α, and 40% a partial cytogenetic remission, which probably delays relapse.
Key wordsLeukemia Prevention Molecular genetics Residual disease Cytogenetics Treatment
Unable to display preview. Download preview PDF.
- 1.Beran M: Treatment of myelodysplastic syndromes, in Kantarjian H M, Frei reich E J (eds):Therapy of Hematopoietic Neoplasia, pp. 35–82. New York, Marcel Dekker (1991).Google Scholar
- 2.Estey E H, Keating M J, Dixon D O, Trujillo J M, McCredie K B, Freireich E J: Karyotype is prognostically more important than the FAB system’s distinction between myelodysplastic syndrome and acute myelogenous leukemia.Hematol Path 1, 203 (1987).Google Scholar
- 3.Kantarjian H M, Talpaz M: Treatment of chronic myelogenous leukemia, in Kantarjian H M, Freireich E J (eds):Therapy of Hematopoietic Neoplasia, pp. 105–174. New York, Marcel Dekker (1991).Google Scholar
- 4.Estey E H, Freireich E J: Therapy for acute myelogenous leukemia, in Kantarjian H M, Freireich E J (eds):Therapy of Hematopoietic Neoplasia, pp. 1–33. New York, Marcel Dekker, (1991).Google Scholar